Beam Therapeutics (BEAM) Equity Ratio (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Equity Ratio for 7 consecutive years, with 0.84 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 25.81% to 0.84 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.84, a 25.81% increase, with the full-year FY2025 number at 0.84, up 25.81% from a year prior.
- Equity Ratio was 0.84 for Q4 2025 at Beam Therapeutics, up from 0.74 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.84 in Q4 2025 to a low of 0.53 in Q3 2022.
- A 5-year average of 0.65 and a median of 0.64 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: dropped 28.32% in 2022, then grew 25.81% in 2025.
- Beam Therapeutics' Equity Ratio stood at 0.56 in 2021, then decreased by 2.5% to 0.55 in 2022, then grew by 22.98% to 0.67 in 2023, then dropped by 1.15% to 0.66 in 2024, then increased by 25.81% to 0.84 in 2025.
- Per Business Quant, the three most recent readings for BEAM's Equity Ratio are 0.84 (Q4 2025), 0.74 (Q3 2025), and 0.75 (Q2 2025).